AR and prostate carcinoma: There are also a whole host of nonsteroidal ligands for AR, developed for various endocrine therapeutic purposes, such as antiandrogens to treat prostate cancer (enzalutamide, apalutamide, darolutamide, and earlier flutamide and bicalutamide) and selective androgen receptor modulators (SARMs) for treating men with hypogonadal conditions (many compounds from GTx) [120].